Literature DB >> 24846594

Advances in and the future of treatments for hepatitis C.

Robert Cheng1, Thomas Tu, Nicholas Shackel, Geoffrey W McCaughan.   

Abstract

Enormous progress has been made in the understanding of the hepatitis C virus and the development of novel therapeutic agents since the identification of the virus 25 years ago. From initial interferon monotherapy providing only 6% viral clearance rate in the 1980s, pharmacotherapeutics has now entered an exciting new era with direct-acting antiviral agents demonstrating viral clearance rates of more than 70%. We are now at the beginning of an era where combinations of direct-acting antiviral agents may pave the way for interferon-free regimens, even improving the viral clearance rate to near 100%.

Entities:  

Keywords:  boceprevir; daclatasvir; danoprevir; deleobuvir; direct-acting antiviral therapy; faldaprevir; hepatitis C; protease inhibitors; simeprevir; sofosbuvir; telaprevir

Mesh:

Substances:

Year:  2014        PMID: 24846594     DOI: 10.1586/17474124.2014.909725

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  4 in total

1.  Hepatitis C surveillance among youth and young adults in New York City, 2009-2013.

Authors:  Catharine Prussing; Katherine Bornschlegel; Sharon Balter
Journal:  J Urban Health       Date:  2015-04       Impact factor: 3.671

2.  Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population.

Authors:  Brent M Tambourine; Arash Sadeghi; Jianing Yang; Karen M Stockl; Heidi C Lew; Brian K Solow; Josephine N Tran
Journal:  Am Health Drug Benefits       Date:  2016-04

3.  Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Authors:  Yoshiki Koizumi; Hirofumi Ohashi; Syo Nakajima; Yasuhito Tanaka; Takaji Wakita; Alan S Perelson; Shingo Iwami; Koichi Watashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

Review 4.  Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.

Authors:  Rohan Janardhan Meshram; Gunderao Hanumantrao Kathwate; Rajesh Nivarti Gacche
Journal:  Arch Virol       Date:  2022-01-28       Impact factor: 2.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.